Study to Identify and Characterize Bacteria Causing Acute Otitis Media in South African Children
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to identify and characterize the bacteria causing acute otitis media episode in HIV-positive and HIV-negative children (>=3 months to <5 years) in South Africa. Middle ear fluid sampling either by tympanocentesis or by careful sampling of spontaneous otorrhoea will be done; nasopharyngeal aspirate and urine sample will also be collected from the subjects.
| Condition | Intervention |
|---|---|
|
Acute Otitis Media |
Procedure: Middle ear fluid, nasopharyngeal aspirate and urine sample. |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in HIV-positive and HIV-negative Children in South Africa |
- Occurrence of bacterial pathogens isolated from middle ear fluid samples in HIV-positive and HIV-negative subjects. [ Designated as safety issue: No ]
- Occurrence of bacterial serotypes. [ Designated as safety issue: No ]
- Antimicrobial susceptibility of different bacteria isolated from middle ear fluid samples as assessed by standard microbiological techniques. [ Designated as safety issue: No ]
- Occurrence of treatment failure of acute otitis media and of recurrent acute otitis media. [ Designated as safety issue: No ]
- Occurrence of spontaneous otorrhoea. [ Designated as safety issue: No ]
- Occurrence of bacteria in acute otitis media cases with treatment failure and in new acute otitis media cases without treatment therapy. [ Designated as safety issue: No ]
- Occurrence of bacteria in acute otitis media cases vaccinated with a pneumococcal vaccine. [ Designated as safety issue: No ]
- Frequency of concurrent respiratory viral infection coinciding with the episode of acute otitis media. [ Designated as safety issue: No ]
- The comparison of above endpoints in HIV-positive and HIV-negative subjects. [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Middle ear fluid, nasopharyngeal aspirate and urine.
| Enrollment: | 265 |
| Study Start Date: | May 2009 |
| Study Completion Date: | May 2010 |
| Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
HIV-negative Group
This group is sub-divided into two sub-groups. One sub-group includes HIV-negative/ presumed negative subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-negative/ presumed negative subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
|
Procedure: Middle ear fluid, nasopharyngeal aspirate and urine sample.
Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
|
|
HIV-positive Group
This group is sub-divided into two sub-groups. One sub-group includes HIV-positive subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-positive subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
|
Procedure: Middle ear fluid, nasopharyngeal aspirate and urine sample.
Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
|
Eligibility| Ages Eligible for Study: | 3 Months to 5 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Children aged >= 3 months and < 5 years seeking healthcare for the treatment of acute otitis media.
Inclusion Criteria:
Inclusion criteria for all subjects:
- Age: >= 3 months and < 5 years at the time of enrolment.
- Signs, symptoms, and conditions:
- One of the functional or general signs of otalgia,, conjunctivitis, fever and either
- Paradise's criteria or
- Spontaneous otorrhoea of less than 24 hours.
- Subject will be included as a treatment failure case.
- Written informed consent obtained from parent or guardian prior to study start.
Inclusion criteria for HIV-positive subjects:
- Documented HIV-positive status as given in subject's medical records. or
- Subjects referred from paediatric HIV clinic.
Inclusion criteria for HIV-negative subjects (including presumed negative children)
- Children who have been tested HIV-negative.
- Children whose mothers volunteer to have tested HIV-negative whilst pregnant with the index case and the child is free to any World Health Organization Grade II stigmata of HIV/acquired immunodeficiency syndrome.
- Children who do not fulfil the World Health Organization staging for HIV infection / immunosuppression.
Exclusion Criteria:
- Hospitalised during the diagnosis of acute otitis media or during treatment.
- Otitis externa or otitis media with effusion.
- Presence of a transtympanic aerator.
- Systemic antibiotic treatment received for a disease other than acute otitis media in the 72 hours prior to enrolment.
- Receiving antimicrobial prophylaxis for recurrent acute otitis media but excluding cotrimoxazole or isoniazid prophylaxis in HIV exposed children.
- Provision of antibiotic by paediatrician/ENT specialist at the enrolment visit prior to the sampling of the middle ear fluid or spontaneous Otorrhoea.
- Children on antibiotics for acute otitis media who are clinically improving.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Study Director, GSK |
| ClinicalTrials.gov Identifier: | NCT01031082 History of Changes |
| Other Study ID Numbers: | 112135 |
| Study First Received: | December 10, 2009 |
| Last Updated: | May 20, 2010 |
| Health Authority: | South Africa: Medicines Control Council |
Additional relevant MeSH terms:
|
Otitis Otitis Media Ear Diseases Otorhinolaryngologic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013